What you should know:
1. Takeda reached an agreement to sell certain products to STADA Arzneimittel AG for $660 million.
2. The drug portfolio includes products sold exclusively in Russia, Georgia and several countries in the Commonwealth of Independent States.
3. This is the fourth transaction Takeda has closed in the last six months and is part of a larger effort the company has to divest $10 billion in non-core assets.
4. Takeda expects the transaction to close in the fourth quarter of fiscal year 2019.
More articles on surgery centers:
3 ASC price transparency insights
Key fall trends for ASCs
Congressman visits Maryland ASC set to open this fall
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.